Red cell membrane abnormalities in sickle cell anemia.
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000628:therapy; D000986:Antisickling Agents / Q000627:therapeutic use; D001381:Azepines / Q000627:therapeutic use; D002463:Cell Membrane Permeability; D004232:Diuretics / Q000627:therapeutic use; D004910:Erythrocyte Membrane / Q000502:physiology / Q000648:ultrastructure*; D004913:Erythrocytes, Abnormal / Q000648:ultrastructure*; D005440:Fluid Therapy; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007473:Ion Channels / Q000378:metabolism; D010084:Oxidation-Reduction; D014667:Vasopressins / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use; D015032:Zinc / Q000627:therapeutic use
D000986:Antisickling Agents; D001381:Azepines; D004232:Diuretics; D006454:Hemoglobins; D007473:Ion Channels; D014667:Vasopressins; D014810:Vitamin E; C006955:cetiedil; D015032:Zinc